Liang Schweizer is the Co-founder, President and CEO of HiFiBiO Therapeutics. Previously, she co-founded Harbour Biomed and served as its CSO, successfully transforming a technology platform company to an antibody drug discovery enterprise.

Before launching her entrepreneurial career, Liang served as Head of Asian Cancer Research at Sanofi, advancing Sanofi’s Asia-Pacific oncology pipeline as well as contributing to global oncology programs from preclinical to clinical efforts. Before joining Sanofi, Liang Schweizer was a director at Bristol-Myers Squibb Company, heading a group of scientists at Leads Discovery and Optimization (LDO), overseeing 60+ in vitro pharmacology projects across different therapeutic areas. Under her leadership, the team made significant contributions to 4 marketed drugs and impacted over 20 clinical candidates. She is also a co-inventor of multiple BMS Immunoncology (IO) clinical candidates.

Liang Schweizer graduated from the University of Science and Technology of China (USTC) majoring in Biology. She received her Master’s degree in Microbial Engineering at the University of Minnesota with minor in Chemical Engineering. Liang earned her Ph.D. in Molecular Biology from the University in Zurich, Switzerland. Her postdoctoral training was with Dr. Harold Varmus, a Nobel Laureate, at Memorial Sloan Kettering Cancer Center (MSKCC), New York.

Jeff He is the Co-founder and Chief Operating Officer of HiFiBiO Therapeutics. He brings more than 20 years of experience in finance, corporate strategy, and operations.

Previously, Mr. He co-founded Harbour BioMed and served as its Chief Financial Officer. Prior to that position, he was the Executive Vice President of ShangPharma/ChemPartner, a leading contract research organization (CRO) based in Shanghai. Mr. He also served as Senior Vice President at Texas Pacific Group (TPG), where he helped to privatize ShangPharma from the NYSE. Prior to TPG, Mr. He held management roles with increasing P&L responsibilities at Danaher/Fluke and Saint-Gobain. In his early career, he was a strategy consultant at Bain & Company and a senior financial analyst at Intel.

Mr. He received his MBA degree from Goizueta Business School at Emory University and his bachelor degree in engineering from Zhejiang University.

Philip Sin is the Chief Financial Officer of HiFiBiO Therapeutics. Mr. Sin brings more than 20 years of experience advising global and local institutions in equity and debt capital raising in international financial centers including the United States, Hong Kong, and China.

Previously, he was the Managing Director of the Cross-Border Business Team at Citi Orient Securities Co. Ltd., where he led where he originated, structured, and executed cross border M&A transactions and fundraising for multinational clients. Prior to Citi Orient Securities, Mr. Sin was Director of Greater China Investment Banking at Citigroup Global Markets Asia Ltd.

Mr. Sin is an angel investor in a medical device company. He graduated Magna cum Laude with a BA from Dartmouth College.

Fred Dom is the Chief Financial Officer of HiFiBiO Therapeutics. Mr. Dom is a serial entrepreneur with expertise in private capital investment and operations.

Previously, he was CEO/Co-founder of HiFiBiO. Prior to that he was CEO of FlexGen (Leiden, the Netherlands) where he spearheaded a commercialization strategy resulting in a successful financing and launch of new, revenue-generating products. Prior to FlexGen, Mr. Dom was CEO and Co-founder of RSP Technology BV, a world-leading supplier of aluminum superalloys to the defense, automotive, aerospace, and electronics industries based on a proprietary process exclusively licensed from Delft University.

Mr. Dom began his career at Rijnvelden BV, focusing on investment in early-stage technology companies. He chairs the Dutch grant advisory committee to the Ministry of Economic Affairs in the field of innovation and entrepreneurship (total budget € 80 million) and he is a member of the “Regiegroep”—14 industrial and academic thought leaders in Dutch Life Science industry. This high-profile group is appointed by the Minister of Economic Affairs, to develop a new industry vision and recommend new policies to support the Dutch Life Science & Health industry (Topsectorplan). Mr. Dom holds a BSc and MSc from Erasmus University.

Francisco Adrian is the Vice President of Biology at HiFiBiO Therapeutics. He is an accomplished scientist with more than 20 years of experience in drug discovery and pharmaceutical research and development.

Previously, Dr. Adrian worked as a Director at the Sanofi Oncology Division, where he led the research efforts for different small molecule and antibody programs in preclinical and clinical development stages. Before joining Sanofi, he was a Group Leader at the Genomics Institute of the Novartis Research Foundation focused on the discovery of novel kinase inhibitors for Oncology indications.

Dr. Adrian graduated in Organic Chemistry and Biochemistry and received his PhD in Molecular Microbiology from the University of Zaragoza, Spain. His postdoctoral training was in Hemato-Immunology at the St Louis Hospital in Paris.

Nicola Beltraminelli is the Vice President of Drug Sciences at HiFiBiO Therapeutics. He is an accomplished biochemist with more than 20 years of industrial experience.

Nicola is leading the global efforts of antibody drug related activities, including reagent generation, immunization, antibody engineering, lead optimization, and characterization, as well as developability assessment and CMC efforts. Prior to joining HiFiBiO Therapeutics, he led a Process Development team at Dictagene, Apoxis and Vivalis for the manufacture of complex biologics from mg scale productions to pilot scale. He successfully transferred the process and methods to a CMO for the generation of Phase I material. Dr. Beltraminelli has strong experience in stable cell line generation, productivity optimization, analytical methods set up and industrialization, process development, scale-up, product characterization methods, product pre-formulation and formulation studies, stability testing, and all the steps needed for the successful manufacture of GMP grade material. In 2010, Dr. Beltraminelli led a more than 20-person team at Vivalis for the discovery and early-stage development of antibodies from humans and other species against a wide range of proprietary targets and managed the R&D facility in Lyon. He actively contributed to the optimization of the antibody discovery platform and in 2015 was appointed as Chief Scientific Officer at BliNK Biomedical SAS.

Dr. Beltraminelli received his PhD in molecular and cellular biology at the Swiss Institute for Experimental Cancer Research (ISREC).

Andreas is leading the company’s global efforts to support pipeline progression by applying the latest advances in data science, machine learning and artificial intelligence on translationally relevant data sets. Dr. Raue brings more than 10 years of experience in computational science, as well as several years of industry leadership experience in immune-oncology antibody development at Merrimack Pharmaceuticals. Andreas received his PhD in theoretical physics from the University of Freiburg where he applied computational modeling and analysis to biological and medical problems. His research has been published in various scientific journals and presented at international conference. Dr. Raue is inspired by the potential of leveraging innovative single-cell technologies and machine learning for the advancement of cancer research.

Xuqiong (Joanna) Wu is the General Counsel at HiFiBiO Therapeutics. She is an accomplished lawyer and scientist with more than 15 years of experience advising life sciences and biotechnology companies.

Previously, she held various in-house counsel positions at three organizations, including a global leader of machinery and engineering, a cutting-edge provider of patient-specific surgical instruments and orthopedic implants, and an emerging biotechnology company. Prior to those positions, Dr. Wu worked at the Boston office of Ropes & Gray LLP, where she advised a variety of clients in the life science industry on intellectual property and regulatory matters.

Dr. Wu received her Juris Doctor (JD) from the law school at the University of California at Berkeley with a certificate in Law & Technology. During law school, she was an editor for the Berkeley Technology Law Journal and the California Law Review, and worked as a law clerk for an intellectual property law firm in San Francisco. Before law school, she received her PhD in physiology from the University of Virginia and conducted research at the Lawrence Berkeley National Laboratory as a recipient of the Alexander Hollaender Distinguished Postdoctoral Fellowship awarded by the U.S. Department of Energy.

Liz Reczek is the Vice President of Global Scientific Operations at HiFiBiO Therapeutics. She is a molecular cancer biologist by training with a diverse background in entrepreneurship and strategic organizational management in early stage biotech companies.

Dr. Reczek previously served as President and CEO of Excelimmune and is a co-inventor on the company’s patent describing a novel method for robust and reproducible manufacture of mixtures of recombinant antibodies. Dr. Reczek also served as CEO of SeqLL, an innovative, single molecule NGS sequencing platform company. More recently, she was an Entrepreneur in Residence with Partners Innovation and built a successful executive management consultant and advisory practice specializing in early stage biotech companies.

Dr. Reczek received a B.A. in Biochemical Sciences from Harvard University, a Ph.D. in Cancer Biology in from MIT and completed a four-year post-doctoral fellowship focused on tumor cell signaling pathways at Brigham and Women's Hospital and Harvard Medical School.

Vincent Tse is the Director of Staff and Strategy at HiFiBiO Therapeutics. His professional experience includes R&D Product Development, Business Development, and Strategy Consulting for both small biotech and large pharma.

Vincent previously worked for Genentech, conducting competitive intelligence for the company’s asthma portfolio. Prior to Genentech, he performed Product and Business Development for Armata Pharmaceuticals, an innovative biotech focused on therapeutics against antibiotic-resistant infections. Most recently, he was a strategy and portfolio analysis consultant for IQVIA with diverse engagements in digital therapeutics, rare disease, and oncology.

Vincent earned an MBA from Duke University Fuqua School of Business, an MS in FDA Regulatory Affairs from Northeastern University, and a BS degree in Physiological Science from UCLA.